Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
79.80    2.10 (2.70%)
Bid:
79.90
Ask:
81.20
Spread: 1.30 (1.627%)
Market Cap: £130.83m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

9 Nov 2016 07:00

RNS Number : 6789O
Synthomer PLC
09 November 2016
 

 

November 9th 2016

Synthomer plc

Q3 Trading update

Positive performance and Full Year 2016 guidance maintained

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th, 2016.

Trading

Europe and North America

Europe and North America has continued to trade well, in line with our expectations and consistent with the positive trends experienced through H1 2016. Q3 reported volumes were in line with last year whilst reported unit margins for the quarter were ahead of Q3 2015 and Q2 2016. Accordingly, with the exception of Paper latex, gross margins across all businesses were stronger than last year. This performance reflects the improved trading environment as well as the Group's focus on efficiency, new product initiatives, strengthened procurement function and investment in business development activities.

Asia and Rest of World

Asia and Rest of World has continued to trade in line with our expectations, with the competitive dynamics in our Asian Nitrile business evolving broadly as expected following the introduction of additional industry capacity.

Reported Asian volumes were marginally lower than last year but sequentially higher than Q2 2016, largely driven by increased volumes in the Asian Nitrile business. As expected, the market environment has led to overall unit margins softening from the highs seen in H2 2015 and H1 2016. Whilst the competitive dynamics in our Asian Nitrile business are continuing to evolve, this downward price pressure has not been as marked as the Group experienced in previous years. We continue to expect full year volumes and margins for this business to be similar to FY 2015.

Hexion PAC

The integration of Hexion PAC is well underway and progressing to plan. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

Foreign currency

The Group has continued to benefit from the translation effect of the ongoing weakness of sterling. Average YTD FX rates are €1.24 and $1.38 which, if unchanged for the remainder of the year, would provide a translational benefit of approximately £10m for the full year.

Financial Position

The Group has generated strong cash flows in Q3, benefitting from Malaysian land sale and South African business sale receipts of £21m and £13m respectively. Net debt has reduced from £215m at 30 June to £159m at 30 September 2016.

The Group balance sheet remains strong with net debt/EBITDA ratio at circa 1.1x.

Outlook

The Board's expectations for Full Year 2016 remain unchanged from the interim results in August. Looking forward, the outlook in 2017 also remains consistent with our previous expectations underpinned by resilient trading in Europe despite a challenging macroeconomic environment, the Asian Nitrile market continuing to evolve broadly in line with our expectations and the ongoing integration of Hexion PAC.

 

Capital Markets Day

Synthomer plc will be hosting a Capital Markets Day for analysts and investors on Thursday December 1st. Senior members of Synthomer's management team will provide an update on strategy as well as present on the Group's two core divisions and R&D and innovation capabilities.

-ENDS-

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Charles Armitstead

Stephen Bennett, Chief Financial Officer

Teneo Blue Rubicon

Tel: + 44 1279 436211

Tel: + 44 207 260 2700

 

 

The Company will hold a conference call for investors and analysts at 0800 GMT today. 

Please dial +44 (0) 808 2370030 entering conference ID: 31555005# to gain access to the call.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBPBLTMBTMBBF
Date   Source Headline
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration
11th Nov 20212:24 pmRNSDirector/PDMR Shareholding
4th Nov 20212:11 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSNew Chief Executive
28th Oct 20213:17 pmRNSResult of Placing
28th Oct 20217:00 amRNSAcquisition
28th Oct 20217:00 amRNSPROPOSED PLACING OF NEW ORDINARY SHARES
30th Sep 20213:08 pmRNSDirectorate Change
10th Sep 20218:23 amRNSDirector Declaration
5th Aug 20217:01 amRNSBoard Update
5th Aug 20217:00 amRNSInterim Results
20th Jul 202112:05 pmRNSSynthomer plc receives Green Economy Mark
19th Jul 20217:00 amRNSTrading Update
14th Jul 202111:02 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSAppointment of Non-Executive Director
6th Jul 202112:37 pmRNSDirector/PDMR Shareholding
25th Jun 202110:01 amRNSFurther re Appointment of Group CEO
23rd Jun 20217:00 amRNSAppointment of Group Chief Executive Officer
18th May 20213:53 pmRNSDirector Declaration
12th May 20212:56 pmRNSDirector Declaration
6th May 20214:17 pmRNSDirector Declaration
6th May 20213:15 pmRNSDirector/PDMR Shareholding
29th Apr 20214:01 pmRNSResult of AGM
21st Apr 20217:00 amRNSQ1 Trading Update
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
30th Mar 202110:56 amRNSAnnual Financial Report
19th Mar 20212:38 pmRNSDirector/PDMR Shareholding
12th Mar 20213:17 pmRNSDirector/PDMR Shareholding
12th Mar 20213:16 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
11th Mar 20219:43 amRNSHolding(s) in Company
4th Mar 202112:43 pmRNSPreliminary results – correction
4th Mar 20217:00 amRNSPreliminary Results year ended 31 December 2020
1st Mar 202112:58 pmRNSHolding(s) in Company
24th Feb 20217:00 amRNSStatement RE: Press Speculation
22nd Feb 20214:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20213:38 pmRNSHolding(s) in Company
14th Jan 20217:00 amRNSPre-Close Trading Update and Board Update
12th Jan 20219:36 amRNSHolding(s) in Company
6th Jan 20219:10 amRNSDirector Declaration
4th Jan 202110:09 amRNSDirector Declaration
23rd Dec 20204:54 pmRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSAppointment of New Chair
18th Nov 20207:00 amRNSInvestor Seminar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.